1
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      A review of exemestane in the management of breast cancer.

      1 ,
      Expert opinion on pharmacotherapy
      Informa Healthcare

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Breast cancer is a major health problem in developed countries. Endocrine therapy is a key component in the management of hormone receptor-positive disease. Although tamoxifen has historically been the gold standard in the first-line management of early and advanced breast cancer, the rise of third-generation aromatase inhibitors in the past decade has resulted in a major shift in endocrine therapy. Clinical trials of aromatase inhibitors including exemestane, an orally active steroidal aromatase inactivator, have demonstrated significant improvements in outcome measures compared with tamoxifen. In early breast cancer, key questions remain regarding the optimal sequence, duration and type of aromatase inhibitors, as well as their long-term safety.

          Related collections

          Author and article information

          Journal
          Expert Opin Pharmacother
          Expert opinion on pharmacotherapy
          Informa Healthcare
          1744-7666
          1465-6566
          Oct 2005
          : 6
          : 13
          Affiliations
          [1 ] Sunnybrook & Women's College Health Sciences Centre, University of Toronto, Ontario, Canada.
          Article
          10.1517/14656566.6.13.2353
          16218894
          30cfbe36-5eb9-4579-9a62-79a00fa9af28
          History

          Comments

          Comment on this article